Ankylosing spondylitis

Patients with ankylosing spondylitis who achieve the ASAS40 end point have less spinal pain at night, less fatigue, better sleep, and improved quality of life.

Secukinumab-treated patients with AS were found to have a numerically higher proportion of radiographic non-progressors compared with biologic-naïve NSAID treated patients.

The study demonstrated the significant benefit of using certolizumab pegol in addition to nonbiologic background medications in patients with nonradiographic axial spondyloarthritis exhibiting objective signs of inflammation.

There is a pressing need to identify barriers to optimizing ankylosing spondylitis therapy within the treatment guidelines.

Study identifies several disease-specific factors associated with the risk of mental disorders in patients with axial spondyloarthritis.

The VIBE technique identified articular destructive damage in patients with axial spondyloarthritis.

Inflammatory bowel disease occurs with an incidence of 1/100 patient-years in early spondyloarthritis.

The use of age- and height-adjusted reference intervals could significantly improve spinal mobility assessment during the course of ankylosing spondylitis disease.